bioRxiv · 10.64898/2026.06.24.734200
Effects of bromodomain and extraterminal domain protein inhibition in a mouse model of Niemann-Pick type C disease
Abstract
Defects in lysosomal lipid handling provoke fatal disorders presenting neurovisceral symptoms with variable onset and life spans. A prime example is Niemann-Pick type C disease (NPCD), where export of cholesterol and other lipids from the endosomal-lysosomal system is impaired due to variants of either NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2). Therapeutic options for NPCD are limited to palliative care and disease-modifying drugs, and there is an unmet need for new treatments. Based on positive effects in patient-derived fibroblasts in vitro, we explored how inhibition of bromodomain and extra-terminal domain (BET) proteins affects a well-established mouse model bearing the frequent I1061T variant of NPC1. Treatment with JQ1, a hydrophobic prototype BET protein inhibitor, induced beneficial but sex-dependent molecular and behavioral changes in mice. Our results indicate bromodomain proteins as therapeutic drug target for NPCD and reveal sex-dependent BET protein signaling in mice.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Parente, M., Barthelemy, A., Caputo, S., Charlery-Adele, N., Tonini, C., Prtvar, D., Tahirovic, S. W., Reibel, S., Pfrieger, F. W., Pallottini, V.. 2026-06-29. Effects of bromodomain and extraterminal domain protein inhibition in a mouse model of Niemann-Pick type C disease. https://doi.org/10.64898/2026.06.24.734200
Cite the original work for its findings. Save a collection to share your selection of sources.